FDA clearance for Brainlab's radiosurgery software
This article was originally published in Clinica
The HybridArc radiosurgery planning software developed by Brainlab has gained 510(k) clearance from the US FDA. The software is designed to increase the efficiency of existing Linac (linear accelerator) technology, to allow fast, high precision volumetric arc radiosurgery treatment without requiring hardware upgrades. HybridArc uses an adaptive dose calculation matrix and can typically calculate stereotactic cranial and spinal radiosurgery plans within a few minutes. It also spares nearby organs and causes lower residual dose compared with other techniques such as rotational intensity modulated radiotherapy, Munich, Germany-based Brainlab says. HybridArc is now approved for use in Europe and the US.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.